The heterogeneity of cancer‐associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment

The prognosis for patients with cancers known for a highly activated stromal reaction, including diffuse‐type (scirrhous) gastric cancer, consensus molecular subtype 4 (CMS4) colorectal cancer, and pancreatic ductal adenocarcinoma, is extremely poor. To explore the resistance of conventional therapy...

Full description

Saved in:
Bibliographic Details
Published inCancer science Vol. 114; no. 1; pp. 16 - 24
Main Authors Yamamoto, Yurie, Kasashima, Hiroaki, Fukui, Yasuhiro, Tsujio, Gen, Yashiro, Masakazu, Maeda, Kiyoshi
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.01.2023
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN1347-9032
1349-7006
1349-7006
DOI10.1111/cas.15609

Cover

Loading…
More Information
Summary:The prognosis for patients with cancers known for a highly activated stromal reaction, including diffuse‐type (scirrhous) gastric cancer, consensus molecular subtype 4 (CMS4) colorectal cancer, and pancreatic ductal adenocarcinoma, is extremely poor. To explore the resistance of conventional therapy for those refractory cancers, detailed classification and investigation of the different subsets of cancer‐associated fibroblasts (CAFs) involved are needed. Recent studies with a single‐cell transcriptomics strategy (single‐cell RNA‐seq) have demonstrated that CAF subpopulations contain different origins and marker proteins with the capacity to either promote or suppress cancer progression. Through multiple signaling pathways, CAFs can promote tumor growth, metastasis, and angiogenesis with extracellular matrix (ECM) remodeling; they can also interact with tumor‐infiltrating immune cells and modulate the antitumor immunological state in the tumor microenvironment (TME). Here, we review the recent literature on the various subpopulations of CAFs to improve our understanding of the cell‐cell interactions in the TME and highlight future avenues for CAF‐targeted therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/cas.15609